Overview
Alzheimer's disease is a slowly progressive brain disorder in which nerve cells in regions that support memory and thinking are gradually lost, leading over years to difficulties with recall, language, orientation and everyday function. It is the leading cause of dementia and becomes more common with age, most often appearing after 65, though a smaller number of earlier-onset cases exist. The condition affects not only the person diagnosed but also families and caregivers, who navigate long-horizon changes in cognition and daily life. A defining feature is that the underlying biology begins many years, even decades, before symptoms appear, which is why research increasingly focuses on the long silent phase. Viewed through a full-body optimization lens, the brain is treated as an organ deeply connected to metabolism, blood vessel health, sleep, inflammation and hormonal signaling, so Dr. Rob considers the whole physiological picture rather than the brain in isolation.
The Underlying Biology
Alzheimer's is defined pathologically by two hallmark lesions: extracellular plaques of aggregated amyloid-beta peptide and intracellular neurofibrillary tangles of hyperphosphorylated tau. Amyloid-beta is cleaved from amyloid precursor protein, and an imbalance between its production and clearance is thought to seed a cascade that promotes tau pathology, synaptic loss and neuronal death, particularly in the hippocampus and cortex. Around these lesions, chronic neuroinflammation involving activated microglia and astrocytes is a consistent feature, and impaired glucose metabolism in affected regions is well documented on imaging. Genetic susceptibility is substantial, with the APOE e4 allele the strongest common risk factor and rare mutations driving early-onset familial forms. Research also emphasizes vascular contributors, cerebral small-vessel disease, insulin signaling and the brain's glymphatic clearance during sleep. Biomarkers now allow the biology to be tracked in living people, including amyloid and tau PET imaging and cerebrospinal-fluid or emerging blood measures such as phosphorylated tau, amyloid-beta ratios and neurofilament light. Because these pathways intersect with systemic metabolic, cardiovascular and inflammatory health, downstream connections across the whole body are actively studied.
What the Research Explores
- Explores how amyloid-beta and tau accumulate over decades and relate to memory and cognitive change
- Investigates whether biomarkers such as APOE genotype, amyloid and tau measures and neurofilament light clarify risk and stage
- Examines the roles of glucose metabolism, insulin signaling and metabolic health in brain aging
- Studies how vascular health, blood pressure and cerebral small-vessel disease may intersect with cognitive decline
- Explores the relationship between sleep, glymphatic clearance, chronic inflammation and long-term brain resilience
- Investigates whole-body optimization strategies aimed at supporting cognitive resilience alongside physician-directed care
Who May Find This Relevant
- People with a family history of Alzheimer's or dementia exploring the underlying biology and risk factors
- Those with early memory or cognitive concerns, or biomarker results such as APOE genotype, seeking context
- Caregivers and family members wanting a clear, science-forward overview of the condition
- Anyone building a physician-guided, labs-informed brain-health and longevity plan with Dr. Rob
Important Considerations
This page is educational only and is not a diagnosis, medical advice, or a treatment plan. Alzheimer's disease is a serious medical condition that must be evaluated and managed with your own physician and appropriate specialists, and any optimization support is decided one-on-one with Dr. Rob based on your labs, history and goals. Individual situations vary; these statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure or prevent any disease.
